A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Trial Profile

A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Lenvatinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2018 Trial design presented at the 32nd Congress of the European Association of Urology.
    • 24 Feb 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
    • 24 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top